NCT06938230 is a NA clinical trial of Health Education Initiative in COVID-19, sponsored by University of Miami.

Who is sponsoring NCT06938230?

NCT06938230 is sponsored by University of Miami.

What drugs are being tested in NCT06938230?

Interventions in NCT06938230: Health Education Initiative.

Is NCT06938230 still recruiting?

NCT06938230 is currently completed. Last updated 6 January 2026.

Are results published for NCT06938230?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-01-06 · How we verify

NCT06938230

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety

Completed NA Results posted Last updated 6 January 2026

What this trial tests

NA trial testing Health Education Initiative in COVID-19 in 112 participants. Completed in 10 June 2023.

Timeline

2 August 2022

Primary endpoint
10 June 2023

10 June 2023

Quick facts

Lead sponsor	University of Miami
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	112
Start date	2 August 2022
Primary completion	10 June 2023
Estimated completion	10 June 2023
Sites	1 location across United States

Drugs / interventions tested

Health Education Initiative

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

University of Miami

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Evaluation of Acceptability of Intervention as Measured by Acceptability Questionnaire Primary · Baseline

Scores range from 1 ("strongly disagree") to 5 ("strongly agree"), with higher scores indicating more knowledge, value, application, or satisfaction. Evaluation was collected directly after the intervention, at baseline.

Group	Value	95% CI
Health Education Initiative	4.47	± 0.89

Evaluation of Confidence in COVID Healthcare Decision Making as Measured by COVID Confidence Questionnaire Primary · 6 months

Scores range from 1 ("strongly disagree") to 5 ("strongly agree"), with higher scores indicating more knowledge, value, application, or satisfaction.

Group	Value	95% CI
Health Education Initiative	4.38	± 0.86

Number of Caregivers Who Received COVID-19 Vaccine Primary · Baseline

The unit of measure is the number of caregivers who received COVID-19 vaccine at baseline

Group	Value	95% CI
Health Education Initiative	35
Control Group	24

Number of Children Who Received COVID-19 Vaccine Primary · Baseline

unit of measure number of children

Group	Value	95% CI
Health Education Initiative	23
Control Group	18

Health Behaviors as Measured by Health Behavior Questionnaire Primary · Baseline

Scores range from 1 ("strongly disagree") to 5 ("strongly agree"), with higher scores indicating greater intent to engage in health behaviors to prevent COVID-19.

Group	Value	95% CI
Health Education Initiative	4.10	± 1.10
Control Group	3.76	± 1.37

Number of Caregivers Who Received COVID-19 Vaccine Primary · 6 months

The unit of measure is the number of caregivers who received COVID-19 vaccine

Group	Value	95% CI
Health Education Initiative	18
Control Group	7

Health Behaviors as Measured by Health Behavior Questionnaire Primary · 6 month

Scores range from 1 ("strongly disagree") to 5 ("strongly agree"), with higher scores indicating greater intent to engage in health behaviors to prevent COVID-19.

Group	Value	95% CI
Health Education Initiative	4.09	± 0.82
Control Group	3.96	± 1.18

PTSD as Measured by the University of California Los Angeles (UCLA) Brief COVID-19 Screen for Child/Adolescent Post Traumatic Stress Disorder (PTSD) Secondary · Baseline, 6 month follow up

Individual item scores range from 0 to 4, individual total sum scores range from 0 to 44 higher scores indicate more symptoms of PTSD. Total sum score ranging from 1-10 is considered "minimal PTSD", total sum score ranging from 11-20 is considered "mild PTSD", total sum scores of 21 or more is considered "potential PTSD".

Baseline

Group	Value	95% CI
Health Education Initiative	5.83	± 6.49
Control Group	5.77	± 8.63

6 month follow up

Group	Value	95% CI
Health Education Initiative	4.6	± 6.7
Control Group	7.74	± 8.27

COVID Anxiety as Measured by the Coronavirus Anxiety Scale Secondary · Baseline, 6 month follow up

individual item score ranges from 0 to 4, individual total sum scores range from 0 to 20 higher scores indicate more symptoms of COVID specific anxiety. Total sum scores of greater than of equal to 9 equals "probable dysfunctional Coronavirus related anxiety".

Baseline

Group	Value	95% CI
Health Education Initiative	0.21	± 0.62
Control Group	1.37	± 3.95

6 month follow up

Group	Value	95% CI
Health Education Initiative	0.83	± 2.28
Control Group	0.42	± 1.22

Number of Children Who Received COVID-19 Vaccine Primary · 6 months

unit of measure number of children

Group	Value	95% CI
Health Education Initiative	11
Control Group	5

Sponsor's own description

The purpose of this study is to compare COVID-19 knowledge, experiences, and health behaviors between participants who received the health initiative and those who did not.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other University of Miami trials

Trials by the same sponsor.

NCT06003712 — Exploring the Effect of Mindfulness on Quality of Life (QoL) in Spinal Cord Injury (SCI) · NA · not yet recruiting
NCT06077071 — MRIdian "RADAR" Trial · NA · not yet recruiting
NCT07472413 — Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project · Phase 3 · not yet recruiting
NCT07322289 — Antibiotic-coated Braided Suture Study · NA · not yet recruiting
NCT07469592 — eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06938230 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Miami
Last refreshed: 6 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06938230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing